speb/financial-data huggingface dataset:
MED balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 9667000.00
MED income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: -3895000.00
MED balance_sheet (annual, 2024-12-31) — Other Payable: 8914000.00
MED balance_sheet (quarterly, 2024-12-31) — Other Payable: 8914000.00
MED balance_sheet (annual, 2024-12-31) — Other Properties: 11155000.00
MED balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 71416000.00
MED balance_sheet (annual, 2024-12-31) — Payables: 43633000.00
MED balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 57663000.00
MED balance_sheet (annual, 2024-12-31) — Prepaid Assets: 9639000.00
MED balance_sheet (quarterly, 2024-12-31) — Prepaid Assets: 9639000.00
MED income_statement (annual, 2024-12-31) — Pretax Income: 3787000.00
MED cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 36000.00
MED cash_flow (quarterly, 2024-12-31) — Proceeds From Stock Option Exercised: 0.00
MED balance_sheet (annual, 2024-12-31) — Properties: 0.00
MED balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
MED cash_flow (annual, 2024-12-31) — Purchase Of Investment: -46595000.00
MED cash_flow (annual, 2024-12-31) — Purchase Of PPE: -7454000.00
MED balance_sheet (annual, 2024-12-31) — Raw Materials: 6704000.00
MED income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 157840000.00
MED income_statement (annual, 2024-12-31) — Reconciled Depreciation: 12707000.00
MED cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -836000.00
MED balance_sheet (annual, 2024-12-31) — Retained Earnings: 176782000.00
MED cash_flow (annual, 2024-12-31) — Sale Of Investment: 27529000.00
MED income_statement (annual, 2024-12-31) — Selling General And Administration: 441745000.00
MED balance_sheet (annual, 2024-12-31) — Share Issued: 10937830.00
MED cash_flow (annual, 2024-12-31) — Stock Based Compensation: 7363000.00
MED balance_sheet (annual, 2024-12-31) — Stockholders Equity: 210109000.00
MED balance_sheet (annual, 2024-12-31) — Tangible Book Value: 210109000.00
MED income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
MED income_statement (annual, 2024-12-31) — Tax Provision: 1696000.00
MED income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
MED balance_sheet (annual, 2024-12-31) — Total Assets: 284213000.00
MED balance_sheet (annual, 2024-12-31) — Total Capitalization: 210109000.00
MED balance_sheet (annual, 2024-12-31) — Total Debt: 16125000.00
MED balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 210109000.00
MED income_statement (annual, 2024-12-31) — Total Expenses: 599585000.00
MED balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 74104000.00
MED balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 69809000.00
MED balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 9943000.00
MED income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 2878000.00
MED balance_sheet (annual, 2024-12-31) — Total Tax Payable: 11020000.00
MED balance_sheet (quarterly, 2024-12-31) — Total Tax Payable: 11020000.00
MED cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 4089000.00
MED balance_sheet (annual, 2024-12-31) — Working Capital: 150243000.00
MED income_statement (quarterly, 2025-03-31) — +Operating Expense: 85507000.00
MED income_statement (quarterly, 2025-03-31) — +Total Revenue: 115728000.00
MED balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 51816000.00
MED balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 34697000.00
MED cash_flow (quarterly, 2025-03-31) — Amortization Of Securities: -190000.00
MED income_statement (quarterly, 2025-03-31) — Basic Average Shares: 10948000.00
MED income_statement (quarterly, 2025-03-31) — Basic EPS: -0.07
MED cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 90928000.00
MED cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -1522000.00
MED balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 14610000.00
MED balance_sheet (quarterly, 2025-03-31) — Capital Stock: 11000.00
MED balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 91717000.00
MED balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 164593000.00
MED cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -194000.00
MED cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -563000.00
MED cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -2054000.00
MED cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 3406000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -5997000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: 1141000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Inventory: 3057000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -41000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Payable: -4856000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -4856000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Prepaid Assets: 73000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: 1141000.00
MED cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -1767000.00
MED cash_flow (quarterly, 2025-03-31) — Changes In Cash: 789000.00
MED balance_sheet (quarterly, 2025-03-31) — Common Stock: 11000.00
MED cash_flow (quarterly, 2025-03-31) — Common Stock Dividend Paid: -194000.00
MED balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 210959000.00
MED cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -369000.00
MED income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 31483000.00
MED balance_sheet (quarterly, 2025-03-31) — Current Assets: 213523000.00
MED balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 6156000.00
MED balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 6156000.00
MED balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 60598000.00
MED cash_flow (quarterly, 2025-03-31) — Deferred Income Tax: 20000.00
MED cash_flow (quarterly, 2025-03-31) — Deferred Tax: 20000.00
MED cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 3280000.00
MED cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 3280000.00
MED income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 10948000.00
MED income_statement (quarterly, 2025-03-31) — Diluted EPS: -0.07
MED income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: -772000.00
MED income_statement (quarterly, 2025-03-31) — EBIT: -1262000.00
MED income_statement (quarterly, 2025-03-31) — EBITDA: 2018000.00
MED cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: 0.00
MED cash_flow (quarterly, 2025-03-31) — End Cash Position: 91717000.00
MED cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -563000.00
MED balance_sheet (quarterly, 2025-03-31) — Finished Goods: 31918000.00
MED cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 1884000.00
MED cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: -7000.00
MED cash_flow (quarterly, 2025-03-31) — Gain Loss On Sale Of PPE: 387000.00
MED balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: 239000.00
MED balance_sheet (quarterly, 2025-03-31) — Gross PPE: 46323000.00
MED income_statement (quarterly, 2025-03-31) — Gross Profit: 84245000.00
MED cash_flow (quarterly, 2025-03-31) — Income Tax Paid Supplemental Data: 2914000.00
MED balance_sheet (quarterly, 2025-03-31) — Income Tax Payable: 2626000.00
MED income_statement (quarterly, 2025-03-31) — Interest Income: 1301000.00
MED income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 1301000.00
MED balance_sheet (quarterly, 2025-03-31) — Inventories Adjustments Allowances: -1169000.00
MED balance_sheet (quarterly, 2025-03-31) — Inventory: 39364000.00
MED balance_sheet (quarterly, 2025-03-31) — Invested Capital: 210959000.00
MED cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -2054000.00
MED balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 8454000.00
MED balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 8454000.00
MED cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -369000.00
MED income_statement (quarterly, 2025-03-31) — Net Income: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: -772000.00
MED cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: -772000.00
MED income_statement (quarterly, 2025-03-31) — Net Interest Income: 1301000.00
MED cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -532000.00
MED income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 1301000.00
MED balance_sheet (quarterly, 2025-03-31) — Net PPE: 46323000.00
MED cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -1522000.00
MED balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 210959000.00
MED balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Assets: 11440000.00
MED balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 11440000.00
MED income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 2018000.00
MED income_statement (quarterly, 2025-03-31) — Normalized Income: -772000.00
MED cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 3406000.00
MED cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 380000.00
MED income_statement (quarterly, 2025-03-31) — Operating Income: -1262000.00
MED income_statement (quarterly, 2025-03-31) — Operating Revenue: 115728000.00
MED balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 10991000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 9566000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: 239000.00
MED income_statement (quarterly, 2025-03-31) — Other Income Expense: 487000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Inventories: 1328000.00
MED cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 1145000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 8725000.00
MED income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 487000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Properties: 46323000.00
MED balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 72876000.00
MED balance_sheet (quarterly, 2025-03-31) — Payables: 54442000.00
MED balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 54442000.00
MED income_statement (quarterly, 2025-03-31) — Pretax Income: 526000.00
MED cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 0.00
MED cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -14991000.00
MED cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -1522000.00
MED balance_sheet (quarterly, 2025-03-31) — Raw Materials: 7287000.00
MED income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 31483000.00
MED income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 3280000.00
MED cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -369000.00
MED balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 176012000.00
MED cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 14459000.00
MED income_statement (quarterly, 2025-03-31) — Selling General And Administration: 85507000.00
MED balance_sheet (quarterly, 2025-03-31) — Share Issued: 10991000.00
MED cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 1930000.00
MED balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 210959000.00
MED balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 210959000.00
MED income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
MED income_statement (quarterly, 2025-03-31) — Tax Provision: 1298000.00
MED income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.21
MED balance_sheet (quarterly, 2025-03-31) — Total Assets: 280011000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 210959000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Debt: 14610000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 210959000.00
MED income_statement (quarterly, 2025-03-31) — Total Expenses: 116990000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 69052000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 66488000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 8454000.00
MED income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: -1262000.00
MED balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 2626000.00
MED balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 0.00
MED cash_flow (quarterly, 2025-03-31) — Unrealized Gain Loss On Investment Securities: -620000.00
MED balance_sheet (quarterly, 2025-03-31) — Working Capital: 152925000.00
MED income_statement (quarterly, 2025-06-30) — +Operating Expense: 77710000.00
MED income_statement (quarterly, 2025-06-30) — +Total Revenue: 105555000.00
MED balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 40260000.00
MED balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 37323000.00
MED cash_flow (quarterly, 2025-06-30) — Amortization Of Securities: 190000.00
MED income_statement (quarterly, 2025-06-30) — Basic Average Shares: 10991000.00
MED income_statement (quarterly, 2025-06-30) — Basic EPS: 0.23
MED cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 91717000.00
MED cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -1378000.00
MED balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 13068000.00
MED balance_sheet (quarterly, 2025-06-30) — Capital Stock: 11000.00
MED balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 101694000.00
MED balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 162673000.00
MED cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -1000.00
MED cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -2000.00
MED cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: 13357000.00
MED cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: -3378000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Account Payable: -13097000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: -7139000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Inventory: 9163000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: -267000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Payable: -20236000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -20236000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Prepaid Assets: 512000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: -7139000.00
MED cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -10828000.00
MED cash_flow (quarterly, 2025-06-30) — Changes In Cash: 9977000.00
MED balance_sheet (quarterly, 2025-06-30) — Common Stock: 11000.00
MED cash_flow (quarterly, 2025-06-30) — Common Stock Dividend Paid: -1000.00
MED balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 216005000.00
MED cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -1000.00
MED income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 28911000.00
MED balance_sheet (quarterly, 2025-06-30) — Current Assets: 206441000.00
MED balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 5924000.00
MED balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 5924000.00
MED balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 46184000.00
MED cash_flow (quarterly, 2025-06-30) — Deferred Income Tax: -20000.00
MED cash_flow (quarterly, 2025-06-30) — Deferred Tax: -20000.00
MED cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 4045000.00
MED cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 4045000.00
MED income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 11060000.00
MED income_statement (quarterly, 2025-06-30) — Diluted EPS: 0.22
MED income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 2480000.00
MED income_statement (quarterly, 2025-06-30) — EBIT: -1066000.00
MED income_statement (quarterly, 2025-06-30) — EBITDA: 2979000.00
MED cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: 0.00
MED cash_flow (quarterly, 2025-06-30) — End Cash Position: 101694000.00
MED cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -2000.00
MED balance_sheet (quarterly, 2025-06-30) — Finished Goods: 23658000.00
MED cash_flow (quarterly, 2025-06-30) — Free Cash Flow: -4756000.00
MED cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -3296000.00
MED cash_flow (quarterly, 2025-06-30) — Gain Loss On Sale Of PPE: 8000.00
MED balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: 179000.00
MED balance_sheet (quarterly, 2025-06-30) — Gross PPE: 43453000.00
MED income_statement (quarterly, 2025-06-30) — Gross Profit: 76644000.00
MED cash_flow (quarterly, 2025-06-30) — Income Tax Paid Supplemental Data: 4190000.00
MED balance_sheet (quarterly, 2025-06-30) — Income Tax Payable: 0.00
MED income_statement (quarterly, 2025-06-30) — Interest Income: 1369000.00
MED income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 1369000.00
MED balance_sheet (quarterly, 2025-06-30) — Inventories Adjustments Allowances: -2307000.00
MED balance_sheet (quarterly, 2025-06-30) — Inventory: 30201000.00
MED balance_sheet (quarterly, 2025-06-30) — Invested Capital: 216005000.00
MED cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: 13357000.00
MED balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 7144000.00
MED balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 7144000.00
MED cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -1000.00
MED income_statement (quarterly, 2025-06-30) — Net Income: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 2480000.00
MED cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 2480000.00
MED income_statement (quarterly, 2025-06-30) — Net Interest Income: 1369000.00
MED cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 14735000.00
MED income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 1369000.00
MED balance_sheet (quarterly, 2025-06-30) — Net PPE: 43453000.00
MED cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -1378000.00
MED balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 216005000.00
MED balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Assets: 11460000.00
MED balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Assets: 11460000.00
MED income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 2979000.00
MED income_statement (quarterly, 2025-06-30) — Normalized Income: 2480000.00
MED cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: -3378000.00
MED cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -3288000.00
MED income_statement (quarterly, 2025-06-30) — Operating Income: -1066000.00
MED income_statement (quarterly, 2025-06-30) — Operating Revenue: 105555000.00
MED balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 10991021.00
MED balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: 179000.00
MED income_statement (quarterly, 2025-06-30) — Other Income Expense: 2572000.00
MED balance_sheet (quarterly, 2025-06-30) — Other Inventories: 1150000.00
MED cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 796000.00
MED balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 7979000.00
MED income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 2572000.00
MED balance_sheet (quarterly, 2025-06-30) — Other Properties: 43453000.00
MED balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 60979000.00
MED balance_sheet (quarterly, 2025-06-30) — Payables: 40260000.00
MED balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 40260000.00
MED balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 13567000.00
MED income_statement (quarterly, 2025-06-30) — Pretax Income: 2875000.00
MED cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 0.00
MED cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -16071000.00
MED cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -1378000.00
MED balance_sheet (quarterly, 2025-06-30) — Raw Materials: 7700000.00
MED income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 28911000.00
MED income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 4045000.00
MED cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -1000.00
MED balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 178492000.00
MED cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 30806000.00
MED income_statement (quarterly, 2025-06-30) — Selling General And Administration: 77710000.00
MED balance_sheet (quarterly, 2025-06-30) — Share Issued: 10991021.00
MED cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 2627000.00
MED balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 216005000.00
MED balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 216005000.00
MED income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
MED income_statement (quarterly, 2025-06-30) — Tax Provision: 395000.00
MED income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.14
MED balance_sheet (quarterly, 2025-06-30) — Total Assets: 269333000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 216005000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Debt: 13068000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 216005000.00
MED income_statement (quarterly, 2025-06-30) — Total Expenses: 106621000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 53328000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 62892000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 7144000.00
MED income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: -1066000.00
MED balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 0.00
MED cash_flow (quarterly, 2025-06-30) — Unrealized Gain Loss On Investment Securities: 620000.00
MED balance_sheet (quarterly, 2025-06-30) — Working Capital: 160257000.00
MED income_statement (quarterly, 2025-09-30) — +Operating Expense: 66240000.00
MED income_statement (quarterly, 2025-09-30) — +Total Revenue: 89409000.00
MED balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 41242000.00
MED balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 38233000.00
MED cash_flow (quarterly, 2025-09-30) — Amortization Of Securities: -515000.00
MED income_statement (quarterly, 2025-09-30) — Basic Average Shares: 10991000.00
MED income_statement (quarterly, 2025-09-30) — Basic EPS: -0.21
MED cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 101694000.00
MED cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -1363000.00
MED balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 12261000.00
MED balance_sheet (quarterly, 2025-09-30) — Capital Stock: 11000.00
MED balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 99526000.00
MED balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 173512000.00
MED cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: 0.00
MED cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 0.00
MED cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -14281000.00
MED cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 12113000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -516000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Inventory: 6996000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 139000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Payable: 5482000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 5482000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: 2233000.00
MED cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 9065000.00
MED cash_flow (quarterly, 2025-09-30) — Changes In Cash: -2168000.00
MED balance_sheet (quarterly, 2025-09-30) — Common Stock: 11000.00
MED cash_flow (quarterly, 2025-09-30) — Common Stock Dividend Paid: 0.00
MED balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 214706000.00
MED cash_flow (quarterly, 2025-09-30) — Common Stock Payments: 0.00
MED income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 27250000.00
MED balance_sheet (quarterly, 2025-09-30) — Current Assets: 207838000.00
MED balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 5471000.00
MED balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 5471000.00
MED balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 46713000.00
MED cash_flow (quarterly, 2025-09-30) — Deferred Income Tax: -648000.00
MED cash_flow (quarterly, 2025-09-30) — Deferred Tax: -648000.00
MED cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 3452000.00
MED cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 3452000.00
MED income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 10991000.00
MED income_statement (quarterly, 2025-09-30) — Diluted EPS: -0.21
MED income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -2261000.00
MED income_statement (quarterly, 2025-09-30) — EBIT: -4081000.00
MED income_statement (quarterly, 2025-09-30) — EBITDA: -629000.00
MED cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 0.00
MED cash_flow (quarterly, 2025-09-30) — End Cash Position: 99526000.00
MED cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 0.00
MED balance_sheet (quarterly, 2025-09-30) — Finished Goods: 19331000.00
MED cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 10750000.00
MED cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: 0.00
MED cash_flow (quarterly, 2025-09-30) — Gain Loss On Sale Of PPE: 606000.00
MED balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 220000.00
MED balance_sheet (quarterly, 2025-09-30) — Gross PPE: 41243000.00
MED income_statement (quarterly, 2025-09-30) — Gross Profit: 62159000.00
MED cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 2912000.00
MED balance_sheet (quarterly, 2025-09-30) — Income Tax Payable: 0.00
MED balance_sheet (quarterly, 2025-09-30) — Inventories Adjustments Allowances: -3993000.00
MED balance_sheet (quarterly, 2025-09-30) — Inventory: 23205000.00
MED balance_sheet (quarterly, 2025-09-30) — Invested Capital: 214706000.00
MED cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -14281000.00
MED balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 6790000.00
MED balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 6790000.00
MED cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 0.00
MED income_statement (quarterly, 2025-09-30) — Net Income: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -2261000.00
MED cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -2261000.00
MED income_statement (quarterly, 2025-09-30) — Net Interest Income: 1426000.00
MED cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: -12918000.00
MED income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 1426000.00
MED balance_sheet (quarterly, 2025-09-30) — Net PPE: 41243000.00
MED cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -1363000.00
MED balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 214706000.00
MED balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Assets: 12108000.00
MED balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 12108000.00
MED income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -629000.00
MED income_statement (quarterly, 2025-09-30) — Normalized Income: -2261000.00
MED cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 12113000.00
MED cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: 606000.00
MED income_statement (quarterly, 2025-09-30) — Operating Income: -4081000.00
MED income_statement (quarterly, 2025-09-30) — Operating Revenue: 89409000.00
MED balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 10991064.00
MED balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: 220000.00
MED income_statement (quarterly, 2025-09-30) — Other Income Expense: -2000.00
MED balance_sheet (quarterly, 2025-09-30) — Other Inventories: 1365000.00
MED cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1518000.00
MED balance_sheet (quarterly, 2025-09-30) — Other Non Current Assets: 7020000.00
MED income_statement (quarterly, 2025-09-30) — Other Non Operating Income Expenses: -2000.00
MED balance_sheet (quarterly, 2025-09-30) — Other Properties: 41243000.00
MED balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 73986000.00
MED balance_sheet (quarterly, 2025-09-30) — Payables: 41242000.00
MED balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 41242000.00
MED balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 11121000.00
MED income_statement (quarterly, 2025-09-30) — Pretax Income: -2657000.00
MED cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 0.00
MED cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -20433000.00
MED cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -1363000.00
MED balance_sheet (quarterly, 2025-09-30) — Raw Materials: 6502000.00
MED income_statement (quarterly, 2025-09-30) — Reconciled Cost Of Revenue: 27250000.00
MED income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 3452000.00
MED cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: 0.00
MED balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 176242000.00
MED cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 7515000.00
MED income_statement (quarterly, 2025-09-30) — Selling General And Administration: 66240000.00
MED balance_sheet (quarterly, 2025-09-30) — Share Issued: 10991064.00
MED cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 910000.00
MED balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 214706000.00
MED balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 214706000.00
MED income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
MED income_statement (quarterly, 2025-09-30) — Tax Provision: -396000.00
MED income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.15
MED balance_sheet (quarterly, 2025-09-30) — Total Assets: 268209000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 214706000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Debt: 12261000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 214706000.00
MED income_statement (quarterly, 2025-09-30) — Total Expenses: 93490000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 53503000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 60371000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 6790000.00
MED income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -4081000.00
MED income_statement (quarterly, 2025-09-30) — Total Other Finance Cost: -1426000.00
MED balance_sheet (quarterly, 2025-09-30) — Total Tax Payable: 0.00
MED cash_flow (quarterly, 2025-09-30) — Unrealized Gain Loss On Investment Securities: -14000.00
MED balance_sheet (quarterly, 2025-09-30) — Working Capital: 161125000.00
MED income_statement (annual, 2025-12-31) — +Operating Expense: 289400000.00
MED income_statement (quarterly, 2025-12-31) — +Operating Expense: 59943000.00
MED income_statement (annual, 2025-12-31) — +Total Revenue: 385788000.00
MED income_statement (quarterly, 2025-12-31) — +Total Revenue: 75096000.00
MED balance_sheet (annual, 2025-12-31) — Accounts Payable: 15066000.00
MED balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 15066000.00
MED balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -68219000.00
MED balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -68219000.00
MED balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 40406000.00
MED balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 40406000.00
MED cash_flow (annual, 2025-12-31) — Amortization Of Securities: -671000.00
MED cash_flow (quarterly, 2025-12-31) — Amortization Of Securities: -156000.00
MED income_statement (annual, 2025-12-31) — Basic Average Shares: 10981000.00
MED income_statement (quarterly, 2025-12-31) — Basic Average Shares: 10991000.00
MED income_statement (annual, 2025-12-31) — Basic EPS: -1.70
MED income_statement (quarterly, 2025-12-31) — Basic EPS: -1.65
MED cash_flow (annual, 2025-12-31) — Beginning Cash Position: 90928000.00
MED cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 99526000.00
MED balance_sheet (annual, 2025-12-31) — Buildings And Improvements: 21735000.00
MED balance_sheet (quarterly, 2025-12-31) — Buildings And Improvements: 21735000.00
MED cash_flow (annual, 2025-12-31) — Capital Expenditure: -5614000.00
MED cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -1351000.00
MED balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 10694000.00
MED balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 10694000.00
MED balance_sheet (annual, 2025-12-31) — Capital Stock: 11000.00
MED balance_sheet (quarterly, 2025-12-31) — Capital Stock: 11000.00
MED balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 89303000.00
MED balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 89303000.00
MED balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 167273000.00
MED balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 167273000.00
MED cash_flow (annual, 2025-12-31) — Cash Dividends Paid: -195000.00
MED cash_flow (quarterly, 2025-12-31) — Cash Dividends Paid: 0.00
MED balance_sheet (annual, 2025-12-31) — Cash Equivalents: 39116000.00
MED balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 39116000.00
MED balance_sheet (annual, 2025-12-31) — Cash Financial: 50187000.00
MED balance_sheet (quarterly, 2025-12-31) — Cash Financial: 50187000.00
MED cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: -564000.00
MED cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 1000.00
MED cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -7928000.00
MED cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -4950000.00
MED cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: 6863000.00
MED cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -5278000.00
MED cash_flow (annual, 2025-12-31) — Change In Account Payable: -23913000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -4303000.00
MED cash_flow (annual, 2025-12-31) — Change In Inventory: 22193000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Inventory: 2977000.00
MED cash_flow (annual, 2025-12-31) — Change In Other Current Assets: -2057000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Other Current Assets: -1888000.00
MED cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -6601000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -816000.00
MED cash_flow (annual, 2025-12-31) — Change In Payable: -23913000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Payable: -4303000.00
MED cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -23913000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -4303000.00
MED cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: 573000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -2245000.00
MED cash_flow (annual, 2025-12-31) — Change In Working Capital: -9805000.00
MED cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -6275000.00
MED cash_flow (annual, 2025-12-31) — Changes In Cash: -1629000.00
MED cash_flow (quarterly, 2025-12-31) — Changes In Cash: -10227000.00
MED balance_sheet (annual, 2025-12-31) — Common Stock: 11000.00
MED balance_sheet (quarterly, 2025-12-31) — Common Stock: 11000.00
MED cash_flow (annual, 2025-12-31) — Common Stock Dividend Paid: -195000.00
MED cash_flow (quarterly, 2025-12-31) — Common Stock Dividend Paid: 0.00
MED balance_sheet (annual, 2025-12-31) — Common Stock Equity: 198920000.00
MED balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 198920000.00
MED cash_flow (annual, 2025-12-31) — Common Stock Payments: -369000.00
MED cash_flow (quarterly, 2025-12-31) — Common Stock Payments: 1000.00
MED income_statement (annual, 2025-12-31) — Cost Of Revenue: 110601000.00
MED income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 22956000.00
MED balance_sheet (annual, 2025-12-31) — Current Accrued Expenses: 8703000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 8703000.00
MED balance_sheet (annual, 2025-12-31) — Current Assets: 201683000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Assets: 201683000.00
MED balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 4603000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 4603000.00
MED balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 4603000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 4603000.00
MED balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 384000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 384000.00
MED balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 384000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 384000.00
MED balance_sheet (annual, 2025-12-31) — Current Liabilities: 42962000.00
MED balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 42962000.00
MED cash_flow (annual, 2025-12-31) — Deferred Income Tax: 11460000.00
MED cash_flow (quarterly, 2025-12-31) — Deferred Income Tax: 12108000.00
MED cash_flow (annual, 2025-12-31) — Deferred Tax: 11460000.00
MED cash_flow (quarterly, 2025-12-31) — Deferred Tax: 12108000.00
MED cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 14242000.00
MED cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 3465000.00
MED cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 14242000.00
MED cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 3465000.00
MED income_statement (annual, 2025-12-31) — Diluted Average Shares: 10981000.00
MED income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 10991000.00
MED income_statement (annual, 2025-12-31) — Diluted EPS: -1.70
MED income_statement (quarterly, 2025-12-31) — Diluted EPS: -1.65
MED income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -18119000.00
MED balance_sheet (annual, 2025-12-31) — Dividends Payable: 295000.00
MED balance_sheet (quarterly, 2025-12-31) — Dividends Payable: 295000.00
MED income_statement (annual, 2025-12-31) — EBIT: -14213000.00
MED income_statement (quarterly, 2025-12-31) — EBIT: -7803000.00
MED income_statement (annual, 2025-12-31) — EBITDA: 29000.00
MED income_statement (quarterly, 2025-12-31) — EBITDA: -4338000.00
MED cash_flow (annual, 2025-12-31) — Effect Of Exchange Rate Changes: 4000.00
MED cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: 4000.00
MED cash_flow (annual, 2025-12-31) — End Cash Position: 89303000.00
MED cash_flow (quarterly, 2025-12-31) — End Cash Position: 89303000.00
MED cash_flow (annual, 2025-12-31) — Financing Cash Flow: -564000.00
MED cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 1000.00
MED balance_sheet (annual, 2025-12-31) — Finished Goods: 18001000.00
MED balance_sheet (quarterly, 2025-12-31) — Finished Goods: 18001000.00
MED cash_flow (annual, 2025-12-31) — Free Cash Flow: 1249000.00
MED cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -6629000.00
MED cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -3310000.00
MED cash_flow (quarterly, 2025-12-31) — Gain Loss On Investment Securities: -7000.00
MED cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: 1373000.00
MED cash_flow (quarterly, 2025-12-31) — Gain Loss On Sale Of PPE: 372000.00
MED balance_sheet (annual, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 234000.00
MED balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 234000.00
MED balance_sheet (annual, 2025-12-31) — Gross PPE: 106681000.00
MED balance_sheet (quarterly, 2025-12-31) — Gross PPE: 106681000.00
MED income_statement (annual, 2025-12-31) — Gross Profit: 275187000.00
MED income_statement (quarterly, 2025-12-31) — Gross Profit: 52140000.00
MED cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 10465000.00
MED cash_flow (quarterly, 2025-12-31) — Income Tax Paid Supplemental Data: 449000.00
MED balance_sheet (annual, 2025-12-31) — Income Tax Payable: 0.00
MED balance_sheet (quarterly, 2025-12-31) — Income Tax Payable: 0.00
MED income_statement (annual, 2025-12-31) — Interest Income: 5516000.00
MED income_statement (annual, 2025-12-31) — Interest Income Non Operating: 5516000.00
MED balance_sheet (annual, 2025-12-31) — Inventories Adjustments Allowances: -4342000.00
MED balance_sheet (quarterly, 2025-12-31) — Inventories Adjustments Allowances: -4342000.00
MED balance_sheet (annual, 2025-12-31) — Inventory: 20228000.00
MED balance_sheet (quarterly, 2025-12-31) — Inventory: 20228000.00
MED balance_sheet (annual, 2025-12-31) — Invested Capital: 198920000.00
MED balance_sheet (quarterly, 2025-12-31) — Invested Capital: 198920000.00
MED cash_flow (annual, 2025-12-31) — Investing Cash Flow: -7928000.00
MED cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -4950000.00
MED balance_sheet (annual, 2025-12-31) — Land And Improvements: 345000.00
MED balance_sheet (quarterly, 2025-12-31) — Land And Improvements: 345000.00
MED balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 6091000.00
MED balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 6091000.00
MED balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 6091000.00
MED balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 6091000.00
MED balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 77369000.00
MED balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 77369000.00
MED cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: -369000.00
MED cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 1000.00
MED income_statement (annual, 2025-12-31) — Net Income: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -18119000.00
MED cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -18672000.00
MED cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -18119000.00
MED income_statement (annual, 2025-12-31) — Net Interest Income: 5516000.00
MED income_statement (quarterly, 2025-12-31) — Net Interest Income: 1420000.00
MED cash_flow (annual, 2025-12-31) — Net Investment Purchase And Sale: -2314000.00
MED cash_flow (quarterly, 2025-12-31) — Net Investment Purchase And Sale: -3599000.00
MED income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: 5516000.00
MED income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 1420000.00
MED balance_sheet (annual, 2025-12-31) — Net PPE: 38462000.00
MED balance_sheet (quarterly, 2025-12-31) — Net PPE: 38462000.00
MED cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -5614000.00
MED cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -1351000.00
MED balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 198920000.00
MED balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 198920000.00
MED balance_sheet (annual, 2025-12-31) — Non Current Deferred Assets: 0.00
MED balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Assets: 0.00
MED balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Assets: 0.00
MED balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Assets: 0.00
MED income_statement (annual, 2025-12-31) — Normalized EBITDA: 29000.00
MED income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -4338000.00
MED income_statement (annual, 2025-12-31) — Normalized Income: -18672000.00
MED income_statement (quarterly, 2025-12-31) — Normalized Income: -18119000.00
MED cash_flow (annual, 2025-12-31) — Operating Cash Flow: 6863000.00
MED cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -5278000.00
MED cash_flow (annual, 2025-12-31) — Operating Gains Losses: -1937000.00
MED cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 365000.00